ASGCT’s Annual Meeting
Let's connect at ASGCT 2026 in Boston to discuss how our integrated CDMO and CRO solutions help cell and gene therapy developers of all sizes and stages advance their life-saving treatments.
May 11–15, 2026 | Boston, Massachusetts | Booth #1749
About ASGCT’s Annual Meeting
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the field’s largest and most comprehensive event, offering unique opportunities to explore cutting-edge research, stay current on emerging technologies, and build career-advancing connections.
This year’s program features more than 750 expert speakers, over 1,500 posters, and specialized sessions on topics such as AI in cell and gene therapy (CGT) and viral and non-viral delivery approaches.
ASGCT 2026 in Boston will provide a platform to connect key decision-makers—including researchers, clinicians, regulators, biotech developers, and service providers—fostering collaboration from basic research through clinical development and commercial manufacturing.
Event details
Date: May 11–15, 2026
Location: Thomas M. Menino Convention & Exhibition Center
Booth Number: #1749
Event Website: https://annualmeeting.asgct.org/
Why Thermo Fisher Scientific?
Advanced therapies, such as cell and gene therapies, have the potential to transform the healthcare industry as we know it, but the transition from translational studies to commercial manufacturing is challenging. An experienced partner can make all the difference.
Thermo Fisher provides integrated CDMO and CRO capabilities for faster, more predictable drug development—helping cell and gene therapy innovators advance their programs at critical transitions. Our flexible services scale and adapt as your program evolves, offering:
- Development designed for scale-up
- GMP readiness and tech transfer support
- Regulatory alignment across program lifecycle
- Clinical supply and cold chain coordination
Visit our team at booth #1749 in the exhibit hall or schedule a one-on-one meeting with our technical experts using the ASGCT Events App to discuss how our integrated CDMO and CRO services for advanced therapies can support your program’s success from beginning to end.
Attend our live session:
Tools and Technology Forum
Title: Enabling >80% reduction in rAAV cost per dose through robotics and scalable high-throughput process and analytical development (HTPAD)
- Date: Wednesday, May 13, 2026
- Time: 4:15–4:30 p.m. EST
- Where: Exhibit Hall
- Speaker: Pouria Motevalian, Ph.D., Director of BioProcess Sciences, Thermo Fisher Scientific
About our speaker:
Dr. Pouria Motevalian leads the Gene Therapy Process and Analytical Development team at Thermo Fisher Scientific, where he oversees CMC development for gene therapy programs from preclinical through late-stage phases. As a member of the Senior Leadership Team at the company’s Plainville, MA vector development and manufacturing site, he provides strategic direction to advance innovative bioprocess technologies and address evolving client needs. Prior to joining Thermo Fisher, Dr. Motevalian led biologics and vaccine process development at Pfizer, where he also championed the integration of digital technologies into R&D. He holds a Ph.D. in chemical engineering from Pennsylvania State University and has contributed to numerous publications, patents, and professional organizations in the field.
Faster, more predictable drug development
We look forward to seeing you at ASGCT 2026 in Boston and exploring how we can work together. To pre-book a meeting with our team, click the button below—we’d love to get you on our calendar.
Stay connected to new discoveries, innovations, and expert scientific opinions.
Follow us on social media for the latest up-to-date event happenings.
We look forward to seeing you soon